Elevated carcinoembryonic antigen [CEA]
ICD-10 R97.0 is a billable code used to indicate a diagnosis of elevated carcinoembryonic antigen [cea].
Elevated carcinoembryonic antigen (CEA) is a laboratory finding often associated with various malignancies, particularly colorectal cancer. CEA is a glycoprotein involved in cell adhesion and is typically produced in fetal tissues. In adults, elevated levels can indicate the presence of certain cancers, but they may also be elevated in benign conditions such as inflammatory diseases, liver disease, and smoking. The clinical significance of elevated CEA levels lies in their use as a tumor marker for monitoring treatment response and disease recurrence in patients with known malignancies. However, it is important to note that CEA is not specific to cancer and should not be used as a standalone diagnostic tool. A comprehensive clinical evaluation, including patient history, physical examination, and additional diagnostic tests, is essential to interpret elevated CEA levels accurately.
Document the patient's history, physical examination findings, and any relevant imaging or lab results that support the need for CEA testing.
Patients with a history of colorectal cancer undergoing surveillance for recurrence.
Ensure that the reason for testing is clearly documented, especially if CEA is elevated in the absence of malignancy.
Document acute symptoms, lab results, and any immediate interventions taken based on elevated CEA levels.
Patients presenting with abdominal pain and elevated CEA levels, requiring urgent evaluation.
Consider the need for rapid assessment of potential malignancy versus benign causes of elevated CEA.
Used to monitor patients with a history of colorectal cancer.
Document the indication for the CEA test and any relevant clinical findings.
In oncology, ensure that the CEA test is linked to the patient's cancer treatment plan.
An elevated CEA level can indicate the presence of certain cancers, particularly colorectal cancer, but it can also be elevated in benign conditions such as liver disease and smoking.
CEA is not recommended for general cancer screening; it is primarily used for monitoring treatment response and detecting recurrence in patients with a history of cancer.
